Breaking News
Get 55% Off 0
🎈 Up Big Today: Find today's biggest gainers with our free screener
Try Stock Screener
Close

bioAffinity Technologies Inc (BIAF)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow bioAffinity Technologies's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.940 -0.034    -3.47%
- Real-time Cboe. Currency in USD
Type:  Equity
Market:  United States
  • Volume: 29,998
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.930 - 0.990
bioAffinity Technologies 0.940 -0.034 -3.47%

NASDAQ:BIAF Financials

 
Explore the NASDAQ:BIAF financials. Find the bioAffinity Technologies financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key financial reports, including the bioAffinity Technologies annual report, the income statement, balance sheet, and cash flow statement. Gain deeper insights with financial ratios that assess the company's performance and stability. Users can customize their view by selecting data from four periods of either annual or quarterly information, making it easy to track the financial performance of bioAffinity Technologies over time.

bioAffinity Technologies, Inc. reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported sales was USD 2.35 million compared to USD 0.298484 million a year ago. Net loss was USD 2 million compared to USD 2.29 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.26 a year ago. Diluted loss per share from continuing operations was USD 0.16 compared to USD 0.26 a year ago. For the nine months, sales was USD 7.15 million compared to USD 0.319143 million a year ago. Net loss was USD 6.07 million compared to USD 5.56 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 0.65 a year ago. Diluted loss per share from continuing operations was USD 0.54 compared to USD 0.65 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

BIAF Income Statement

Gross margin TTM 35.03%
Operating margin TTM -89.13%
Net Profit margin TTM -90.16%
Return on Investment TTM -76.57%
 Total Revenue  Net Income
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023
Total Revenue 2.35 2.4 2.41 2.21
Gross Profit 0.91 0.99 0.833 0.548
Operating Income -1.97 -2.09 -1.95 -2.34
Net Income -2 -2.11 -1.96 -2.37

BIAF Balance Sheet

Quick Ratio MRQ 0.82
Current Ratio MRQ 1.02
LT Debt to Equity MRQ 0.69%
Total Debt to Equity MRQ 55.09%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023
Total Assets 6.55 6.66 8.05 8.22
Total Liabilities 3.43 3.22 2.79 3.37
Total Equity 3.12 3.43 5.26 4.86

BIAF Cash Flow Statement

Cash Flow/Share TTM -0.53
Revenue/Share TTM 0.69
Operating Cash Flow  -68.67%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -1.71 -1.53 -2.35 -1.62
Cash From Investing Activities -0.009 -0.028 -0.041 0.013
Cash From Financing Activities 1.67 -0.091 2.02 -0.085
Net Change in Cash -0.045 -1.65 -0.368 -1.69
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BIAF Comments

Write your thoughts about bioAffinity Technologies Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Charles Resheske
Charles Resheske May 16, 2024 10:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this story has just begun 1 st innings
Charles Resheske
Charles Resheske Mar 12, 2024 7:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy and hold
shevon blair
shevon blair Sep 01, 2022 10:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Bull run
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email